Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Olema Oncology (Nasdaq: OLMA) announced that Sean P. Bohen, M.D., Ph.D., President and CEO will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced that Sean P. Bohen, M.D., Ph.D., President and CEO will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast and any accompanying presentation materials will be accessible in the Events and Presentations section of Olema's investor relations website at ir.olema.com, and a recording will be posted after the event.
Details
News Market Reaction – OLMA
On Jan 5, the day this news came out, OLMA closed 0.71% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 13, 2025
- Scheduled conference presentation
- Presentation time PT
- 11:15 a.m. PT
- J.P. Morgan presentation slot
- Presentation time ET
- 2:15 p.m. ET
- J.P. Morgan presentation slot
- Share price
- $25.28
- Pre-news current price
- 52-week high
- $36.2591
- 52-week trading range
- 52-week low
- $2.86
- 52-week trading range
- Market cap
- $2,003,998,075
- Pre-news valuation
Historical Context
-
Reported inducement stock option grants to new employees under 2022 plan.
-
Announced participation in Evercore healthcare conference with webcast access.
-
Closed $19.00 per share underwritten equity offering with $218.5M gross proceeds.
-
Priced $190.0M public offering of 10,000,000 common shares at $19.00.
-
Announced proposed common stock and pre-funded warrant offering under shelf.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast of the presentation and any accompanying materials will be available in the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.